Adjusted for imbalances in baseline characteristics or nonadherence, a nominally significant reduction in the primary composite end point was found. 41 Additionally, further prespecified secondary analyses of EVOLVE demonstrated a significant risk reduction for parathyroidectomy 40 or the development of calciphylaxis 42 with the use of cinacalcet.
← all excerpts
Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
1
—
—